{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:01:04Z","timestamp":1781715664954,"version":"3.54.5"},"reference-count":13,"publisher":"Norwegian Medical Association","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.20.0411","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T08:38:17Z","timestamp":1592383097000},"source":"Crossref","is-referenced-by-count":0,"title":["Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?"],"prefix":"10.4045","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-2760","authenticated-orcid":false,"given":"Anne Hege","family":"Aamodt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-1094","authenticated-orcid":false,"given":"Marte H.","family":"Bj\u00f8rk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling A.","family":"Tronvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik Alnes","family":"Buanes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Jacob","family":"Stovner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8793","authenticated-orcid":false,"given":"Dan","family":"Atar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Ruan\u00a0Q, Yang\u00a0K, Wang\u00a0W et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32125452&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00134-020-05991-x","DOI":"10.1007\/s00134-020-05991-x"},{"key":"ref=2","unstructured":"Patel\u00a0AB, Verma\u00a0A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence? JAMA 2020; 323: 1769\u201370. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32208485&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjama.2020.4812"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Vaduganathan\u00a0M, Vardeny\u00a0O, Michel\u00a0T et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382: 1653\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32227760&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMsr2005760","DOI":"10.1056\/NEJMsr2005760"},{"key":"ref=4","unstructured":"Folkehelseinstituttet. Statistikk fra Reseptregisteret. www.reseptregisteret.no\/prevalens.aspx Lest 13.5.2020."},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Hoffmann\u00a0M, Kleine-Weber\u00a0H, Schroeder\u00a0S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271\u2013280.e8. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32142651&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.cell.2020.02.052","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Regla-Nava\u00a0JA, Jimenez-Guarde\u00f1o\u00a0JM, Nieto-Torres\u00a0JL et al. The replication of a mouse adapted SARS-CoV in a mouse cell line stably expressing the murine SARS-CoV receptor mACE2 efficiently induces the expression of proinflammatory cytokines. J Virol Methods 2013; 193: 639\u201346. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23911968&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jviromet.2013.07.039","DOI":"10.1016\/j.jviromet.2013.07.039"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Soler\u00a0MJ, Barrios\u00a0C, Oliva\u00a0R et al. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep 2008; 10: 410\u20134. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18775121&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs11906-008-0076-0","DOI":"10.1007\/s11906-008-0076-0"},{"key":"ref=8","unstructured":"Fang\u00a0L, Karakiulakis\u00a0G, Roth\u00a0M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8. doi: 10.1016\/S2213-2600(20)30116-8. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32171062&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS2213-2600(20)30116-8"},{"key":"ref=9","unstructured":"ESC. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang Lest 13.5.2020."},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Hirakawa\u00a0Y, Arima\u00a0H, Webster\u00a0R et al. Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. J Hypertens 2016; 34: 781\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26938813&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FHJH.0000000000000841","DOI":"10.1097\/HJH.0000000000000841"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Mancia\u00a0G, Rea\u00a0F, Ludergnani\u00a0M et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020; 382. doi: 10.1056\/NEJMoa2006923. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32356627&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa2006923","DOI":"10.1056\/NEJMoa2006923"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Mehra\u00a0MR, Desai\u00a0SS, Kuy\u00a0S et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 N Engl J Med 2020; 382. doi: 10.1056\/NEJMoa2007621. Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa2007621","DOI":"10.1056\/NEJMc2021225"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Reynolds\u00a0HR, Adhikari\u00a0S, Pulgarin\u00a0C et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020; 382. doi: 10.1056\/NEJMoa2008975. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32356628&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa2008975","DOI":"10.1056\/NEJMoa2008975"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Gir ACE-hemmere og angiotensinreseptorantagonister \u00f8kt risiko for alvorlig covid-19?"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:59:40Z","timestamp":1781711980000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2020\/05\/debatt\/gir-ace-hemmere-og-angiotensinreseptorantagonister-okt-risiko-alvorlig-covid-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,16]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.20.0411","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]}}}